Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK3152314A · 1 trial · 1 indication
safety assessment includes AEs, vital signs, ECG, clinical laboratory tests.
DAS28 at Day 28 and DAS28 at Day 56
DAS28 scores on Day 56 (Part B and C)
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | matching placebo |
| GSK315234A | ACTIVE_COMPARATOR | Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose |
| Name | Type | Description |
|---|---|---|
| GSK3152314A | DRUG | Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: * Males or females between 18 and 75 years of age, inclusive. * All subjects must use acceptable contraception (as defined in the study restriction section) to ensure that no pregnancies occur during the course of the study and for at least 12 weeks after dosing for males and fo...
GSK3152314A is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development. The drug has been studied in a completed Phase 2 trial that evaluated its safety and efficacy in patients with rheumatoid arthritis.
The molecular target of GSK3152314A has not been disclosed in available information. The drug is a small molecule being developed by GSK plc for rheumatoid arthritis, and its specific mechanism of action has not been publicly detailed.
GSK3152314A is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this investigational drug for the treatment of rheumatoid arthritis.
GSK3152314A is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 2 clinical trial has been completed, and the drug remains under investigation for rheumatoid arthritis.
GSK3152314A has been studied in one clinical trial, identified as NCT00674635. This was a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of GSK315234A in patients with rheumatoid arthritis. The trial enrolled 135 participants and has been completed.
Yes, GSK3152314A is the same as GSK315234A. The clinical trial NCT00674635 refers to the drug as GSK315234A, while the drug name is also listed as GSK3152314A. Both names refer to the same investigational drug being developed for rheumatoid arthritis.